HER-2/neu Protein Expression in Canine Mammary Adenocarcinoma

국문 초록 (Abstract)

개에서의 유선 종양진단은 총 49 case 중에서 Human epidermal growth factor receptor (HER-2/neu, c-erbB-2), Epidermal growth factor receptor (EGFR), Activated leukocyte cell adhesion molecule (ALCAM) 등 면역조직화학적염색법을 실시하였다. 우선 49 case를 두 그룹으로 즉: 양성종양그룹 (22 case)과 악성종양그룹 (27case)으로 구분하였다. 면역조직화학적염색법의 분석결과 HER-2/neu의 발현은 양성종양에서는 31.8% (7/22), 악성종양에서는 29.6% (8/27)의 발현율을 보였고, EGFR의 발현은 양성종양에서는 27.3% (6/22), 악성종양에서는 22.2% (6/27)의 발현율을 보였으며, ALCAM의 발현은 양성종양에서는 40.9% (9/22), 악성종양에서는 7.4%(2/27)의 발현율을 보였다. 결론적으로 개에서의 유선종양진단의 발현율은 사람에서 보고된 것(25%~30%)과 비슷하게 나타났으며 임상진단분야에서 HER-2/neu 항체로 개에서의 유선종양진단에서 유용한 평가수단으로 적용될 수 있으리라 사료된다.

다국어 초록 (Multilingual Abstract)

In this study to evaluate the involvement of EGFR, HER-2/neu and ALCAM (CD166) oncogene products in canine mammary neoplastic lesions, sections of archived paraffin-embedded samples of 49 mammary tumors were analyzed immunohistochemically using antibodies against human EGFR and HER-2/neu and ALCAM. These 49 tumors were divided into 2 groups: 22 benign (19 adenoma, 3 benign mixed tumors) and 27 malignant tumors (2 simple adenocarcinomas, 5 complex adenocarcinomas, 3 solid carcinoma, 5 sclerosing carcinoma, 8 malignant mixed tumors and 4 malignant myoepithelioma). As a result of immunostaining, 31.8% (7/22) of the benign tumors and 29.6% (8/27) of the malignant tumors expressed the HER-2/neu oncogene product, EGFR expression was detected in 27.3% (6/22) of benign tumors and in 22.2% (6/27) of the malignant tumors. ALCAM expression was detected in 40.9% (9/22) of benign tumors and in 7.4% (2/27) of the malignant tumors. These results suggest that some of the biological and morphological characteristics of the tumor are associated with canine mammary gland tumors, as also reported for human breast cancer, the possibility of using anti-HER-2/neu antibodies in the treatment of canine mammary tumors.

목차 (Table of Contents)

• Introduction
• Materials and Methods
• Results
• Discussion
• Acknowledgment
• References

참고문헌 (Reference)

1 Thomas, C. J., "Veterinary pathology. pp. 1190-1200, In: Genital system" Williams & Wilkins 1997

2 Shih, C., "Transforming genes of carcinomas and neuroblastomas introduced introduced into mouse fibroblasts" 290 : 261-264, 1981

3 Gullick, W. J, "The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer" 5 : 55-66, 1990

4 Schechter, A. L., "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen" 312 : 513-516, 1984

5 Klijn, J. G., "The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review of 5232 patients" 13 : 3-17, 1992

6 Krupp, M. N., "Synthesis, turnover and down-regulation of epidermal growth factor receptors in human A431 epidermal carcinoma cells and skin fibroblasts" 257 : 11489-11496, 1982

7 Toi, M., "Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytocehmical study" 29 : 51-58, 1994

8 Nakopoulou, L. L., "Prognostic significance of the co-expression of p53 and c-erbB-2 protein in breast cancer" 179 : 31-38, 1996

9 Miller, W. R., "Prognostic factors ABC of breast disease" 309 : 1573-1576, 1994

10 Lacroix, H., "Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases" 4 : 145-151, 1989

11 Arai, F., "Mesenchymal stem cells in perichondrium express activated leukocyte cell adhesion molecule and participate in bone marrow formation" 195 : 1549-1563, 2002

12 Degen, W., "MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule)" 152 : 805-813, 1998

13 Rachamandra, S., "Immunohistochemical distribution of c-erbB-2 in in situ carcinoma: a detailed morphological analysis" 161 : 7-14, 1990

14 Bartkova, J., "Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ" 21 : 1164-1167, 1990

15 Rungsipipat, A., "Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors" 61 : 27-32, 1999

16 Anudep, RUNGSIPIPAT, "Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors" 61 (61): 27-32, 1999

17 Slamon, D. J., "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene" 235 : 177-182, 1987

18 Ahern, T. E., "Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines" 57 : 693-696, 1996

19 Moller, P., "Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast" 414 : 157-164, 1989

20 Salomon, D. S., "Epidermal growth factor-related peptides and their receptors in human malignancies" 19 : 183-232, 1995

21 Sainsbury, J. R., "Epidermal growth factor receptors on human breast cancers" 72 : 186-188, 1985

22 Nicholson, R. I., "Epidermal growth factor receptor expression in breast cancer: association with responses to endocrine therapy" 29 : 117-125, 1994

23 Bowen, M. A., "Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand" 181 : 2213-2220, 1995

24 Harris, C. C, "Clinical implication of the p53 tumor suppressor gene" 329 : 1318-1327, 1993

25 Brodey, R. S., "Canine mammary gland neoplasms" 19 : 61-90, 1983

26 Pauletti, G., "Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemisty" 18 : 3651-3664, 2000

27 Corbel, C., "An antigen expressed by avian neuronal cells is also expressed by activated T lymphocytes" 141 : 99-110, 1992

28 Ali, I. U., "Amplification of c-erbB-2 and aggressive human breast tumors" 240 : 1795-1798, 1988

29 Rosen, A, "Addiction to phenmetrazine hydrochloride and its psychiatric implications" 59 : 722-726, 1960

30 van Kempen, L. C., "Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin" 156 (156): 769-774, 2000

31 King, J. A, "Activated leukocyte cell adhesion molecule in breast cancer:Prognostic indicator.Breast Cancer Res.6,R478-R487" 6 : R478-R478, 2004

32 Ohneda, O., "ALCAM (CD166): its role in hematopoietic and endothelial development" 98 : 2134-2142, 2001

33 Fidler, I. J, "A necropsy study of canine malignant mammary neoplasm" 151 : 710-715, 1967